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Microglia are pivotal in the pathogenesis of AIDS dementia, as they serve as the major target of HIV infection in the CNS. In
addition, activation of microglia correlates best with clinical dementia. Although the -chemokine RANTES/CCL5 is important in
modulating HIV infection as well as cellular activation, no information is available regarding how its expression is regulated in
microglia by HIV-1. Here we report that RANTES/CCL5 expression is induced in microglia by HIV-1, but that this requires infection
by HIV-1. This conclusion was supported by (1) the delayed kinetics coinciding with viral replication; (2) the lack of effect of X4
viruses; (3) inhibition by the reverse transcriptase inhibitor AZT, and (4) the lack of effect of cytokine antagonists or antibodies.
Interestingly, RANTES/CCL5 production was dependent on the viral accessory protein Vpr, in addition to Nef, demonstrating a
novel role for Vpr in chemokine induction in primary macrophage-type cells. Furthermore, the specific p38 MAP kinase inhibitor
SB203580 augmented chemokine expression in microglia, indicating a negative role played by p38. These data suggest uniqueINTRODUCTION
Microglia are endogenous brain macrophages that
function in maintaining the homeostasis of the brain
(Dickson and Lee, 1997; Perry and Gordon, 1988; Gehr-
mann et al., 1995). They provide the first line of defense
after brain injury, as activation of microglial cells is the
first detectable change following various CNS insults
(Hickey and Kimura, 1988; Lee et al., 1996). Microglial
cells, in addition to perivascular macrophages, serve as
major targets for HIV-1 infection in the CNS (Dickson et
al., 1994; Watkins et al., 1990; Pumarola-Sune et al., 1987;
Cosenza et al., 2002), and infection of the CNS by HIV-1
produces characteristic clinicopathological features re-
ferred to as AIDS dementia (Navia et al., 1986a,b; Budka
et al., 1991). Microglia in the brains of patients are acti-
vated and express a number of immune and toxic mol-
ecules that can lead to neuronal damage and dysfunc-
tion (Dickson et al., 1994; Lipton and Gendelman, 1995;
Kaul and Lipton, 1999). Microglial activation could occur
through direct interactions with the virus or viral prod-
ucts, or through interactions with other infected or acti-
vated cells (Lipton and Gendelman, 1995; Benveniste,
1994; Dickson et al., 1994; Griffin, 1997). Since microglial
cells reside within the CNS parenchyma and can survive
for the lifespan of an individual, infected microglia also
serve as a viral reservoir.
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342Microglial cells express low levels of CD4, the primary
receptor for HIV-1 (Jordan et al., 1991; Ghorpade et al.,
1998). In addition, microglial infection is dependent on
the expression of CCR5 (He et al., 1997; Albright et al.,
1999; Kitai et al., 2000; Dragic et al., 1996; Deng et al.,
1996) and can be inhibited by chemokines (RANTES/
CCL5, MIP-1/CCL2, and MIP-1/CCL3, with RANTES/
CCL5 being the most potent (He et al., 1997; Albright et
al., 1999; Kitai et al., 2000). In addition to the critical role
of CCR5 in HIV-1 infection in vivo (Huang et al., 1996),
studies also demonstrate that endogenous -chemo-
kines play important roles in inducing an antiviral state
independent of CCR5 (Zagury et al., 1998; Liu et al., 1999).
Consistent with this notion, we previously showed that
endogenous RANTES/CCL5 functions as an inhibitor of
HIV infection in primary cultures of human fetal microglia
(Kitai et al., 2000). However, variable effects have been
associated with exogenous RANTES/CCL5 ranging from
marked inhibition to enhancement of HIV-1 expression
(Ghorpade et al., 1998; Appay and Rowland-Jones, 2001;
Si et al., unpublished observations). These results under-
score the importance of understanding the endogenous
expression of RANTES/CCL5.
RANTES/CCL5 is probably a relevant chemokine for
AIDS dementia because elevated levels of RANTES/
CCL5 have been found in the cerebrospinal fluids of
these patients (Kelder et al., 1998). Both HIV-1 and in-
flammatory mediators that are expressed in these brains
(Griffin, 1997; Zhao et al., 2001) have the potential tofeatures of RANTES/CCL5 regulation by HIV-1 in human micr
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stimulate production of RANTES/CCL5. RANTES/CCL5
has been shown to be induced by cytokines and viraloglial c
okine
components (recombinant HIV-1 proteins) in astrocytes,
microglia, and macrophages (Barnes et al., 1996; Miya-
moto et al., 2000; Hua and Lee, 2000; McManus et al.,
2000); more recently, various HIV-1 isolates have also
been shown to induce -chemokines in macrophages
independent of viral replication (Choe et al., 2001). How-
ever, no information is available on whether RANTES/
CCL5 expression can be induced in microglial cells fol-
lowing exposure to HIV-1. We report in this study that
HIV-1 induces RANTES/CCL5 in microglia and that viral
replication is necessary. Our results also show that Vpr
and Nef are necessary for efficient viral replication and
chemokine expression in microglia. Together, our results
support the notion that HIV-1 accessory proteins play
important roles in macrophage and microglial pathoge-
nicity.
RESULTS
HIV-1ADA induces mRNA for RANTES/CCL5, IP-10/
CXCL10, and MCP-1/CCL2 in microglia following
chronic exposure
To determine the effect of HIV infection on chemokine
expression by microglia, total RNA extracted from micro-
glial cultures was analyzed using a human chemokine
RPA kit from PharMingen. Results from a representative
experiment are illustrated in Fig. 1. In uninfected control
cultures (mock), mRNA for MIP-1/CCL4, MIP-1/CCL3,
MCP-1/CCL2, and IL-8/CXCL8 (from top to bottom) was
readily detectable, as previously described (Hua and
Lee, 2000). In microglia exposed to HIV-1, mRNA for
RANTES/CCL5 and IP-10/CXCL10 were newly induced
and that for MCP-1 was enhanced. However, chemokine
mRNA were induced after 6 days of HIV exposure but not
after 4 h. MIP-1/CCL3 and MIP-1/CCL4 mRNA were
only slightly induced (Day 6), consistent with the protein
data that show requirements for both HIV-1 and GM- or
M-CSF for induction in microglia (data not shown: Si et
al., 2002). IL-8/CXCL8 mRNA expression did not change.
In contrast, IFN-mediated chemokine induction was
rapid, taking only 4 h. Thus, HIV-1 induced RANTES/
CCL5, IP-10/CXCL10, and MCP-1/CCL2 mRNA over long-
term culture, consistent with a dependence on viral rep-
lication.
HIV-1 induces RANTES/CCL5 secretion from
microglial culture in a time- and a dose-dependent
manner
We next compared RANTES/CCL5 mRNA expression
and protein production. Microglial culture supernatants
were collected weekly for 4 weeks in cultures inoculated
with varying infectious doses. As shown in Fig. 2, HIV-
mediated RANTES/CCL5 expression was dependent on
the viral dose: both 500 and 2000 TCID50 of HIV-1 induced
RANTES/CCL5 with varying kinetics, whereas 30 and 125
TCID50 of HIV-1 induced low to insignificant levels of
RANTES/CCL5, consistent with the level of viral replica-
tion (p24) in these cultures (not shown). RANTES/CCL5
was first detected at 7–14 days of infection and not at 1
or 3 days, consistent with the kinetics of mRNA induction
(Fig. 2 and data not shown).
FIG. 1. RPA analysis of chemokine mRNA expression in HIV-1-in-
fected microglia. Microglial cultures at 0.5 106 cells per 100-mm Petri
dish were exposed to HIV-1ADA at 2000 TCID50, as described under
Materials and Methods. For controls, microglial cells were exposed to
PBMC supernatants (Mock) or IFN at 10 ng/ml. Total RNA harvested
at either 4 h or 6 days following exposure was analyzed. Data show that
HIV-1 induced RANTES/CCL5, IP-10, and MCP-1 mRNA in microglia
after 6 days of infection (lane 2) but not after 4 h (lane 4). IFN potently
induced mRNA for multiple chemokines in microglia (lane 5). Results
are representative of two independent experiments with similar results.
FIG. 2. HIV-1 induces RANTES/CCL5 in microglia in a time- and a
dose-dependent manner. Human fetal microglia were exposed to dif-
ferent concentrations of HIV-1ADA and the production of RANTES/CCL5
in culture supernatants was analyzed by ELISA. Values are mean SD
from triplicate wells and are expressed as noncumulative concentra-
tions of RANTES/CCL5 in weekly culture supernatants. Data are rep-
resentative of three separate experiments with similar results.
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RANTES/CCL5 induction requires infection
To determine whether reverse transcription was nec-
essary for induction of RANTES/CCL5, we infected mi-
croglia with HIVADA in the presence of the reverse tran-
scriptase inhibitor 3-azido-deoxythymidine (AZT). As
shown in Fig. 3A, AZT prevented RANTES/CCL5 expres-
sion in HIV-infected microglia, demonstrating that viral
reverse transcription is required. In addition, heat-killed
HIV-1 was unable to induce RANTES/CCL5, demonstrat-
ing that surface interaction of the viral components with
microglia is not sufficient for RANTES/CCL5 expression
(Fig. 3B).
X4 HIV-1 isolates do not induce RANTES/CCL5
production in microglia
Microglia were exposed to the same concentrations of
HIV-11648 or HIV-11650, two primary X4 HIV-1 clinical iso-
lates, or to HIV-1ADA, and RANTES/CCL5 induction was
compared (Fig. 3C). As shown, exposure to X4 viruses
did not induce RANTES/CCL5 in microglia. Neither p24
nor multinucleated giant cells were detected in the X4
virus-infected cultures (not shown). Thus, X4 HIV-1 does
not induce chemokine in microglia. Another R5 virus,
BAL, and an X4R5 virus, 89.6, also induced RANTES/
CCL5 in microglia (not shown).
Cytokines are not responsible for RANTES/CCL5
expression in HIV-infected microglia
In human microglial cells, RANTES/CCL5 can be in-
duced by IL-1, TNF, and IFN (McManus et al., 2000;
Kitai et al., 2000). These proinflammatory and antiviral
cytokines are also induced by HIV-1 in macrophages
(Merrill et al., 1989; Genis et al., 1992; Nottet et al., 1995).
Therefore, we explored the possibility that cytokines
produced in HIV-infected cultures could contribute to
RANTES/CCL5 production. Microglial cultures were
treated with specific antagonist or antibody to IL-1, TNF,
or IFN before exposure to HIV-1, and the production of
RANTES/CCL5 was determined. As shown in Fig. 4, none
of the cytokine inhibitors reduced RANTES/CCL5 expres-
sion, demonstrating that cytokines were not responsible
for RANTES/CCL5 production by HIV-1 (Figs. 4A and 4B).
As controls, microglia were treated with recombinant
IL-1, TNF, or IFN: they showed production of RANTES/
CCL5, which was inhibited by specific antagonist or
antibody (Figs. 4C and 4D).
Role of viral accessory protein Vpr in RANTES/CCL5
expression
Studies suggest several important roles played by the
HIV-1 accessory proteins in the host cell function. We
tested the role of the 14-kDa HIV-1 accessory protein,
Vpr, in microglial RANTES/CCL5 expression. We used
Vpr-deficient (Vpr) provirus bearing an R5 env [pHXB-
(BAL)] to generate infectious virus, and we compared its
ability to produce RANTES/CCL5 with that of a Vpr virus.
The results are summarized in Table 1 and a case is also
illustrated in Fig. 5. Vpr virus induced RANTES/CCL5 in
microglia in kinetics consistent with viral production; AZT
blocked RANTES/CCL5 production in two of three cases,
and incompletely in one case (Fig. 5: see Discussion).
Vpr virus induced RANTES/CCL5 in amounts signifi-
cantly less than Vpr virus, with many cases showing no
induction over mock-infected cultures (Table 1). p24 lev-
els also showed significant differences in four of seven
cases (Vpr  Vpr) and no differences in three of seven
cases, demonstrating that Vpr can upregulate viral pro-
duction. However, there was not always a one-to-one
correlation with Vpr’s ability to upregulate RANTES/CCL5
vs p24, demonstrating that chemokine and p24 were not
necessarily coregulated by Vpr (Table 1). However, there
was significant positive correlation between the p24 and
RANTES/CCL5 levels in both the Vpr (P  0.007) and
Vpr (P  0.015) groups by Spearman rank order cor-
relation (Sigma Stat: Jandel Scientific).
FIG. 3. Effect of AZT, heat-inactivation, and X4 strains of HIV-1. (A)
Microglia were exposed to live HIV-1ADA in the presence of 10 M
3-azido-deoxythymidine (AZT). (B) Microglia were exposed to HIV-1ADA
treated with heat at 56°C for 1 h. (C) Microglia were exposed to 500
TCID50 of HIV-11648 or HIV-11650, two nonlaboratory-adapted X4 isolates,
or to HIV-1ADA. Levels of RANTES/CCL5 protein in Day 7 and 14 culture
supernatants were determined by ELISA. Values are cumulative che-
mokine production from each well (0–7 and 0–14 days). Mean  SD
from triplicate wells. One of three separate experiments with similar
results are shown. P  0.05 compared with Mock.
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Role of Nef in RANTES/CCL5 production
The viral accessory protein Nef has been shown to
play a role in HIV-induced MIP-1/CCL3 and MIP-1/
CCL4 production in macrophages (Swingler et al., 1999).
Therefore, we tested whether Nef was also necessary
for microglial RANTES/CCL5 expression. Microglial cul-
tures were infected with either Nef or Nef HIV-1ADA and
the amounts of RANTES/CCL5 in weekly supernatants
were compared. The results demonstrate a marked dif-
ference between Nef and Nef HIVADA in their ability to
induce RANTES/CCL5 (Table 2). Nef HIV-1ADA induced
small amounts of RANTES/CCL5, but significantly higher
than mock infection. Both Nef and Nef viruses repli-
cated well in microglia, but Nef virus induced much
higher p24 than Nef virus, indicating that Nef has a
significant positive role in viral replication in microglia. A
positive correlation was observed between p24 and
RANTES/CCL5 levels in these cultures. However, this
was not statistically significant (P  .05), most likely due
to the small number of cases examined.
Role of MAP kinases in HIV-mediated induction of
RANTES/CCL5
MAP kinases play important roles in viral replication
and chemokine expression (Jacque et al., 1998; Kumar et
al., 1996; Yang et al., 1999; Zybarth et al., 1999; Popik and
Pitha, 1998). We tested the role of ERK and p38 MAP
kinases in RANTES/CCL5 production by using specific
pharmacological inhibitors (Davies et al., 2000). Inhibi-
tors of p38 kinase (SB203580) and MEK (upstream of
ERK: PD98059) were tested at concentrations shown not
to be toxic for microglia in 14-day cultures. The results
showed that the p38 kinase inhibitor SB203580 signifi-
cantly enhanced RANTES/CCL5 and MIP-1 production
from microglia (Fig. 6). A control compound, SB202474,
did not have this effect (not shown). The MEK inhibitor
PD98059 had no consistent effect on -chemokine pro-
duction. These results suggest that the p38 kinase has
an inhibitory role in the activation of RANTES/CCL5 in
microglia.
DISCUSSION
HIV-1 replication is required for -chemokine
induction in microglia
In this report, we demonstrated that HIV-1 induces
RANTES/CCL5 in microglial cells. Induction required vi-
rus replication. Consistent with this, the delayed kinetics
of RANTES/CCL5 expression (both mRNA and protein)
coincided with the viral production, and T-tropic virus,
heat-killed virus, or the AZT-treated cultures did not
FIG. 4. Cytokine antagonists fail to block HIV-1-induced RANTES/CCL5. Microglial cultures were treated with IL-1ra (20–2000 ng/ml), sTNFR
(40–4000 ng/ml), mouse anti-IFN IgG2 (1–10 g/ml) or normal mouse IgG2a, in the presence or absence of HIV-1 (A, B). Cytokine inhibitors were
replenished following medium change. RANTES/CCL5 production was determined by ELISA. As controls for inhibitor activity, microglia were treated
with recombinant cytokines at 10 ng/ml for 24 h in the presence of inhibitors (C, D). Values are from triplicate wells (mean SD), and the experiments
are repeated three time with the same results. *P  0.05 vs without inhibitor or with mIgG2a.
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cause RANTES/CCL5 production. We also found that
HIV-1 induces MIP-1/CCL3 and MIP-1/CCL4 in micro-
glia and this is viral replication-dependent as well as
stimulation with colony-stimulating factors (Si et al.,
2002). A similar requirement for HIV-1 replication for
-chemokine (MIP-1/CCL3, MIP-1/CCL4, and MCP-1/
CCL2) production has been established in MDM
(Schmidtmayerova et al., 1996; Mengozzi et al., 1999;
Swingler et al., 1999). Our study contrasts with earlier
studies on MDM which failed to detect RANTES/CCL5
following HIV-1 infection (Swingler et al., 1999). This
discrepancy may reflect either intrinsic differences be-
tween microglia and MDM or technical differences. For
instance, we observed that the amounts of RANTES/
CCL5 produced by microglia are at least an order of
magnitude lower than those of MIP-1/CCL3 and MIP-
1/CCL4 regardless of the inducing stimuli applied (Mc-
Manus et al., 2000; Kitai et al., 2000). In addition, culture
additives such as colony-stimulating factors alter both
the chemokine expression and the antiviral responses to
the chemokines (Amzazi et al., 1998; Si et al., 2002).
Sufficient variability exists in the macrophage and micro-
glial culture protocols with respect to the use of these
growth factors, which could contribute to the divergent
results.
Although the role of viral infection in chemokine induc-
tion is well established, our study does not exclude
alternative mechanisms for HIV-1 to induce chemokine
synthesis, especially those mediated by Env. Recent
studies demonstrated that MDM can be acutely acti-
TABLE 1
Expression of RANTES/CCL5 and p24 Antigen in Microglial Cultures Infected with Vpr and Vpr HIV
Experiment
(Case No.)
Input virus (p24)
(ng/mL)
Incubation time
(days)
Microglial RANTES/CCL5 (pg/ml) Microglial p24 (ng/ml)
Mock
Vpr (*P  0.05)
(vs Mock)
Vpr (*P  0.05)
(vs Vpr) Vpr
Vpr (*P  0.05)
(vs Vpr)
1 5 14a 129 25d 119 45 312 73* 0.44 0.18 0.69 0.33
21 332 16 325 95 713 102* NDe ND
2 5 14a 134 51 72 48 444 18* 1.07 0.12 0.90 0.08
3 40 5c 15 8 25 10 116 15* 4.58 0.39 4.6  0.53
4 10 21b 133 25 137 5 182 33 0.87 0.33 6.23 0.94*
20 21 133 25 167 8 299 86* 2.02 0.35 9.94 2.53*
40 21 133 25 133 19 376 70* 2.92 0.45 21.6  1.74*
5 40 14a 391 15 352 22 436 8* 6.80 0.94 21.8  0.25*
6 10 7 NDe 207 18 357 45* 2.69 0.65 5.71 0.77*
20 7 ND 170 28 480 44* 5.98 1.09 10.0  1.59*
40 7 ND 203 23 710 94* 12.6  2.14 16.1  1.74*
7 40 14a 660 16 1304 328* 2381 163* 19.3  1.18 27.1  2.56*
21 715 156 3170 222* 4199 138* 36.1  1.68 44.4  1.68*
Note. Results from seven experiments each using cells from different brain cases.
a Induction of RANTES/CCL5 by virus not seen at 7 days.
b Induction of RANTES/CCL5 by virus not seen at 7 and 14 days.
c Full kinetics are shown in Fig. 5.
d Mean  SD from triplicate wells.
e Not determined.
* P  0.05 by Student’s t test.
FIG. 5. RANTES/CCL5 induction by Vpr and Vpr HIV-1 in microglia.
Microglia were infected with virus [pHXB(BAL)-R or pHXB(BAL)-R] at
40 ng/ml of p24, as described in Fig. 2 legend. RANTES/CCL5 and p24
levels are measured by ELISA in culture supernatants collected at
indicated time points. These results indicate that HIV-1 viral accessory
protein Vpr is necessary for RANTES/CCL5 induction in microglia.
Values are mean  SD from triplicate wells and represent cumulative
values. *P  0.05 Mock vs Vpr; and Vpr vs Vpr.
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vated by gp120 as well as HIV-1 belonging to R5 or X4 to
release large amounts of chemokines (Del Corno et al.,
2001; Fantuzzi et al., 2001; Choe et al., 2001). Further-
more, earlier studies also demonstrated that recombi-
nant preparations of Tat can also induce -chemokines
in astrocytes and microglia (Conant et al., 1998; McMa-
nus et al., 2000). These results are interesting because
HIV-1 Env can transduce signals in macrophages and T
cells through surface interactions with both CCR5 and
CXCR4, even when viral entry to macrophages is re-
stricted to the viral strains utilizing CCR5 (Del Corno et
al., 2001; Popik and Pitha, 1998). Although the possibility
exists for microglia to interact with virion-associated or
shed Env or Tat following HIV-1 inoculation, in our stud-
ies, chemokine induction appears to be correlated with
viral replication. Chemokines were not detectable on
Day 1 or 3 following inoculation with HIV-1 and chemo-
kine mRNA was not detected at 4 h (Fig. 1). These results
are consistent with the interpretation that the microglial
cultures failed to achieve sufficient levels of gp120 or Tat
necessary to activate microglia and/or that Env or Tat
induces cellular signaling cascades different from those
induced by viral infection (see below). Additionally, the
expression of CD4 and CCR5 on human fetal microglia is
undetectable by FACS analysis (Zhao et al., unpublished
observations), while neutralization experiments show
their involvement in HIV-1 infection (Kitai et al., 2000). As
such, the low numbers of viral receptors expressed on
microglia (Jordan et al., 1991; He et al., 1997), compared
with MDM, could also give rise to the differential che-
mokine responses elicited by gp120 or inactivated virus.
In order to elucidate the mechanisms underlying
RANTES/CCL5 induction by HIV-1 in microglia, we ana-
lyzed several candidate host and viral factors possibly
playing a role in this process. We first asked whether
RANTES/CCL5 was induced by endogenous cytokines
present in these cultures. Proinflammatory stimuli such
as IL-1 and TNF, bacterial endotoxin, and an antiviral
cytokine, IFN, are all capable of inducing chemokines
in microglia (McManus et al., 1998, 2000; Kitai et al.,
2000; Hua and Lee, 2000). However, our results show
that cytokine inhibitors did not diminish the production of
RANTES/CCL5. Moreover, HIV-infected human fetal mi-
croglia did not release TNF or IL-1, producing only
intracellular IL-1 in selected cultures (Liu and Lee:
unpublished observations), consistent with the notion
that costimulatory signals are needed, in addition to
virus, to induce cytokine release (Genis et al., 1992;
Nottet et al., 1995). Moreover, cytokine induction by HIV-1
is known to be independent of productive viral infection
(Merrill et al., 1989; Genis et al., 1992; Nottet et al., 1995).
Together, these results illustrate that the mechanisms
involved in HIV-mediated chemokine expression are dif-
ferent from those involved in cytokine expression. Al-
though anti-IFN failed to inhibit RANTES/CCL5 expres-
sion in microglia, a minor role for endogenous interferon
could not be excluded because the antibody was not
highly effective in blocking the activity of recombinant
IFN, and because other isoforms of type I IFN may also
be present in microglial cultures.
The role of viral accessory proteins
We investigated the role of viral accessory proteins in
-chemokine expression in microglia and identified both
Vpr and Nef as necessary factors. HIV-1 Vpr is a 14-kDa
auxiliary protein which facilitates HIV infection of nondi-
viding cells by promoting nuclear transport of the viral
reverse transcription complex (Heinzinger et al., 1994).
Vpr has also been shown to enhance viral transcription,
induce G2 cell cycle arrest in proliferating T cells, and
modulate apoptosis (Connor et al., 1995; Felzien et al.,
1998; He et al., 1995; Rogel et al., 1995; Ayyavoo et al.,
1997). Using mutated HXB viruses (R and R) bearing
BaL Env, we tested the role of Vpr in chemokine and viral
p24 expression. In microglial cultures derived from sev-
eral different brain cases, we found that Vpr, but not
Vpr, HIV induced RANTES/CCL5. There were two cases
TABLE 2
Expression of RANTES/CCL5 and p24 Antigen in Microglial Cultures Infected with Nef and Nef HIV
Experiment
(Case No.)
Input virus (p24)
(ng/mL)
Incubation time
(days)
Microglial RANTES/CCL5 (pg/ml) Microglial p24 (ng/ml)
Mock
Nef (*P  0.05)
(vs Mock)
Nef (*P  0.05)
(vs Nef) Nef
Nef (*P  0.05)
(vs Nef)
1 200 7 256 66a 289 40 544 136* 7.12 1.38 14.9  0.94*
14 262 78 416 76* 972 71* 15.2  3.02 33.8  0.88*
2 50 7 105 27 196 26* 1916 271* 7.23 2.39 20.85 0.70*
14 131 12 298 61* 5249 122* 8.55 2.39 42.83 1.18*
200 7 105 27 276 23* 1941 116* 9.03 1.80 19.06 0.56*
14 131 12 426 96* 4549 295* 14.4  1.18 41.1  0.20*
Note. Results are from two experiments each using cells from two different donors.
a Mean  SD from triplicate wells.
* P  0.05 by Student’s t test.
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where the Vpr virus also induced RANTES/CCL5, albeit
at lower levels than Vpr virus. The Vpr virus replicated
better than the Vpr virus in approximately half of the
cases, but clearly Vpr was not required for replication,
consistent with the idea that other viral proteins such as
matrix protein (MA) or integrase could substitute for Vpr
for nuclear import (Subbramanian et al., 1998). We did not
find Vpr activity to be viral dose-dependent, at least in the
dose ranges we adopted, as has been suggested by
Subbramanian et al. (1998). Our results are more consis-
tent with those of Balliet et al. (1994), who reported that
replication of Vpr-deficient virus was restricted in MDM
even at high virus input.
Our study uncovered a novel function of Vpr. That is,
that this viral protein is necessary, as is Nef (see below),
in the induction of RANTES/CCL5. We surmise that both
input virus-associated Vpr and de novo synthesized Vpr
contributed to chemokine synthesis, given that AZT did
not always inhibit the expression of RANTES/CCL5 (Fig.
5). Therefore, it would be important to determine if Vpr
alone could induce chemokines in the absence of other
viral-related factors, as has been shown for Nef (Swing-
ler et al., 1999), and these studies are under way. Vpr has
been shown to activate the transcription factors NF-B
and NF-IL6 (C/EBP) in MDM (Roux et al., 2000). There-
fore, it is conceivable that Vpr, in sufficient amounts,
FIG. 6. Effect of MAP kinase inhibitors in HIV-1-induced chemokine expression in microglia. Microglia were pretreated with PD98059 or SB203580
at indicated doses for 1 h and then exposed to HIV-1ADA (A, B) or pHXB[BaL] (C). Drugs were added back, whenever culture medium was changed.
Chemokines and p24 levels were measured by ELISA. Mean  SD from triplicate wells, cumulative values. Data are representative of two or three
separate experiments with similar results. *P  0.05 vs no drug.
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could stimulate NF-B independent of viral expression,
and this could activate transcription of chemokine genes.
We also found that Nef augmented chemokine induc-
tion in microglia. It is interesting that in MDM, Swingler et
al. (1999) showed that MIP-1 and MIP-1 were pro-
duced in a viral-replication- and Nef-dependent manner
and that transduction of Nef plasmid also induced che-
mokines, demonstrating Nef alone provided a signal for
macrophage activation. We compared Nef and Nef
HIV-1ADA for their role in RANTES/CCL5 and p24 produc-
tion in microglia and found that Nef increased both.
Interestingly, Nef enhanced p24 production in microglia
significantly, as did Vpr. Although direct comparison can-
not be made because these viral strains are not iso-
genic, these data suggest that Nef plays a significant
role, similar to that described for Vpr, in viral expression
in microglia. This is consistent with the findings of a role
for Nef in MDM (Balliet et al., 1994). Therefore, it is
feasible that Nef mediated its chemokine-inducing effect
in microglia at least in part by enhancing viral replication.
Our results support the general notion that Nef plays a
key role in the pathogenesis of HIV-1 disease by modu-
lating macrophage activation and survival (Briggs et al.,
2001; Geleziunas et al., 2001; Mahlknecht et al., 2000;
Swingler et al., 1999). These effects of Nef are dependent
on the cellular expression of Nef and, therefore, are
dependent on productive infection of the target cells. Our
results are in line with the emerging view that viral
accessory genes such as Vpr and Nef that play nones-
sential or negative roles (in peripheral blood mononu-
clear cells (PBMC) or T-cell lines) may be critical in
macrophages. Our results in microglial cells extend such
notions and suggest that these viral accessory genes
may play critical roles in the pathogenesis of neuroAIDS.
In vivo studies have demonstrated that Nef-deficient vi-
ruses are attenuated (Deacon et al., 1995; Learmont et
al., 1999; Kirchhoff et al., 1995; Kestler et al., 1991) and
that Nef, in addition to macrophage tropism, constitutes
an important determinant for neurovirulence in the SIV
model (Flaherty et al., 1997).
Role of MAP kinases
The MAP kinases are a group of protein kinases that
are activated in response to extracellular stimuli through
dual phosphorylation at conserved threonine and ty-
rosine residues (Cobb and Goldsmith, 1995; English et
al., 1999). In T cells, MAP kinase activation occurs fol-
lowing virus/gp120 binding to cells, which modulates
subsequent cytokine and chemokine expression (Popik
and Pitha, 1998; Popik et al., 1998). Interestingly, the
ability to stimulate p38 and JNK MAP kinases in T cells
was correlated with the CCR5 usage of the virus,
whereas ERK MAP kinase was activated by either R5 or
X4 virus (Popik and Pitha, 1998). In macrophages, CCR5
engagement by gp120 also activated p38 and JNK (Del
Corno et al., 2001). Whether MAP kinase activation oc-
curs following productive viral infection is not known. We
analyzed the role of p38 and ERK MAP kinases in HIV-
induced chemokines in microglia using specific inhibi-
tors (Davies et al., 2000). Inhibition of p38 kinase en-
hanced RANTES/CCL5 and MIP-1/CCL4 production by
microglia. p38 inhibition also occasionally led to aug-
mentation of p24 production, but the two (chemokine and
p24) were independently regulated by p38. Furthermore,
inhibition of p38 also stimulated chemokine production
in uninfected microglia, suggesting that p38 is a general
negative regulator in microglial chemokine expression.
In sum, these results are suggestive of the presence of a
negative regulatory factor(s) downstream of p38 affecting
both viral and cellular gene expression. As infection in
MDM is also negatively regulated by p38 (Zybarth et al.,
1999), there may be a common signaling mechanism in
primary macrophages. ERK inhibition produced no sig-
nificant effect, although robust ERK phosphorylation was
detected in infected microglial cultures by Western blot
analysis (not shown).
In microglia, viral replication-dependent expression of
RANTES/CCL5 and MIP-1/CCL4 may represent an im-
portant antiviral mechanism in the CNS preventing
spread of the virus. However, because of the multiple
functions demonstrated for chemokines, including re-
cruitment and activation of inflammatory cells, the impli-
cations of this study are complex. Understanding of the
specific viral and host elements involved inflammatory
gene expression may offer opportunities for fine-tuning
the CNS environment in favor of an antiviral and neuro-
protective state. For example, we find p38 to be potently
stimulatory for astrocyte production of candidate neuro-
toxins, nitric oxide and TNF (Hua et al., 2002). Thus, p38
appears to play an opposite role in astrocyte iNOS/TNF
expression and microglial chemokine expression. Poten-
tially, these target gene- and cell-specific effects of MAP
kinases can be used to selectively suppress cytokines
and neurotoxins.
MATERIALS AND METHODS
Human fetal microglial culture
Human fetal CNS cell cultures were prepared from
second trimester abortuses as described (Lee et al.,
1992, 1993). Primary mixed CNS mixed cultures were
prepared by enzymatic and mechanical dissociation of
the cerebral tissue followed by filtration through nylon
meshes of 230- and 130-pore sizes. Single-cell suspen-
sion was plated at 1–10  106 cells/mL in DMEM (Cell-
gro, supplemented with 4.5 g/L glucose, 4 mM L-glu-
tamine, and 25 mM HEPES)-supplemented 5% fetal calf
serum (Gemini Bio-products, Woodland, CA), penicillin
(100 U/mL), streptomycin (100 g/mL), and fungizone
(0.25 g/mL) (GIBCO) for 2 weeks, and then microglial
cells were collected by aspiration of the culture medium.
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Monolayers of microglia were prepared in 100-mm tissue
culture dishes at 106 cells/10 mL medium or in 96-well
tissue culture plates at 4 104 cells/0.1 mL medium. Two
to four hours later, cultures were washed twice to re-
move nonadherent cells (neuronal and astrocytes) and
microglial culture were highly pure, consisting of 98%
CD 68 cells.
Preparation of mutant viruses
Cos-7 cells were cultured in DMEM containing 10%
FCS at 37°C and 5% CO2 at 10
6 cells per 100-mm dish.
Twenty-four hours later, cells were transfected with 20
g of Vpr [pHXB (BAL)-R] or Vpr [pHXB (BAL)-R]
plasmids by calcium phosphate precipitation (Connor et
al., 1995) or by lipofection using the Lipofectamine re-
agents (Life Technologies, Bethesda, MD) following
the manufacturer’s instructions. Culture medium was
changed 24 and 48 h posttransfection, and then the
virus-containing supernatants were collected at 72 h and
kept frozen at 80°C until use. The amounts of virus in
the transfected Cos-7 cell supernatants were determined
by p24 ELISA. Microglia were exposed to culture super-
natants containing 5–40 ng/mL of p24. Nef-deficient and
wild-type (WT) HIV-1ADA proviruses were obtained from
the laboratory of Dr. Mario Stevenson (University of Mas-
sachusetts, Boston, MA) and propagated in Cos-7 cells
(Swingler et al., 1999), as described for the Vpr mutant
viruses. Microglia were exposed to culture supernatants
containing 50–200 ng/mL of p24 as determined by ELISA,
as exposure to lower doses induced less consistent
chemokine induction (not shown).
Infection of microglia with HIV-1
HIV-1ADA, originally donated by Dr. Howard Gendel-
man, and the two X4 HIV-1 isolates, HIV-11650 and HIV-
11648, were obtained from ARRRP and were propagated in
activated human PBMC. Briefly, normal PBMC were ex-
posed to the HIV-1 isolates in the presence of IL-2 at 48 h
after activation with PHA in RPMI containing 10% FCS.
On Days 7 and 14, culture supernatants were collected;
p24 levels were determined by ELISA (NEN Life Science
Products, Inc., Boston, MA) and kept frozen at 80°C
until use. Control culture supernatants for mock infection
were prepared in PBMC stimulated with PHA and IL-2
without HIV-1. Tissue culture infectivity dose (TCID50) was
determined by serial dilution of the viral stock in fresh
PBMCs as the dose that infected half of quadruplicate
cultures. Microglia cultures in medium devoid of fungi-
zone were infected with HIV-1ADA at 2000 TCID50 (approx-
imately 5–20 ng/mL p24) per well or at indicated doses in
96-well plates for 16 h at 37°C, and then washed and
incubated with fresh medium. Culture supernatants were
collected on Days 7, 14, 21, and 28 postinfection for
measurements of RANTES/CCL5 and HIV-1 p24 levels.
Reagents
AZT was purchased from Sigma Chemical Co. (St.
Louis, MO). Recombinant human IL-1 was a gift from
the National Cancer Institute and recombinant human
TNF, IL-1 receptor antagonist (IL-1ra) and soluble TNF
receptor (sTNFR) were purchased from R&D Systems
(Minneapolis, MN). IFN and a monoclonal antibody to
human IFN were purchased from PBL Biomedical Lab-
oratories (New Brunswick, NJ). Control mouse IgG2a
was purchased from Pharmingen (San Diego, CA). MAP
kinase inhibitors, SB203580, SB202474 (control for
SB203580), and PD98059, were purchased from Calbio-
chem (San Diego, CA) and Cell Signaling (Beverly, MA),
respectively, and stocks were prepared in DMSO.
Chemokine ELISA
The concentration of RANTES/CCL5 in control and
HIV-infected microglial culture supernatants were deter-
mined by ELISA using antibody pairs purchased from
R&D systems following the manufacturer’s instructions.
Ribonuclease protection assay
Total RNA was extracted using TRIZOL (Molecular
Research Center, Cincinnati, OH) following the manufac-
turer’s instructions (Hua and Lee, 2000). RNA was ana-
lyzed using the PharMingen human chemokine RPA kit
according to the manufacturer’s instructions. Images
were developed by autoradiography.
Data analysis
Each figure displays data from triplicate wells
(mean  SD) from a single representative experiment.
Experiments were repeated 2–10 times using different
brain cases with similar results. For statistical analysis of
the data, the following analyses were performed: (1)
Student’s t test for comparison of values in two different
treatment conditions; (2) one-way ANOVA followed by
Scheffer’s multiple comparison procedure for comparing
multiple treatment conditions; and (3) Spearman Rank
Order test for correlation of p24 and RANTES/CCL5 ex-
pression across different brain cases. P values less than
0.05 were considered significant.
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